Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors
Adlai Nortye (NASDAQ: ANL), a global clinical-stage biotechnology company, has appointed Roger Sawhney, M.D. to its Board of Directors, effective August 8, 2024. Dr. Sawhney brings nearly 30 years of financial and strategic expertise in the biopharma industry. He currently serves as the Chief Financial Officer of LB Pharmaceuticals and has held leadership positions at various pharmaceutical and investment firms, including Garuda Therapeutics, Omega Therapeutics, KKR & Co. Inc., and Novartis AG.
CEO Carsten Lu welcomed Dr. Sawhney, highlighting his valuable financial experience from both pharmaceutical corporate and healthcare investment perspectives. Dr. Sawhney expressed enthusiasm for joining Adlai Nortye's mission to develop innovative cancer therapies and transform deadly cancer into a chronic and eventually curable disease.
Adlai Nortye (NASDAQ: ANL), un'azienda globale di biotecnologie in fase clinica, ha nominato Roger Sawhney, M.D. nel proprio Consiglio di Amministrazione, con effetto dall'8 agosto 2024. Il Dr. Sawhney porta con sé quasi 30 anni di esperienza finanziaria e strategica nel settore biopharma. Attualmente ricopre il ruolo di Direttore Finanziario di LB Pharmaceuticals e ha occupato posizioni di leadership in diverse aziende farmaceutiche e di investimento, tra cui Garuda Therapeutics, Omega Therapeutics, KKR & Co. Inc. e Novartis AG.
Il CEO Carsten Lu ha dato il benvenuto al Dr. Sawhney, sottolineando la sua preziosa esperienza finanziaria sia dal punto di vista delle aziende farmaceutiche che degli investimenti nel settore sanitario. Il Dr. Sawhney ha espresso entusiasmo nell'unirsi alla missione di Adlai Nortye di sviluppare terapie innovative per il cancro e trasformare il cancro mortale in una malattia cronica e, infine, curabile.
Adlai Nortye (NASDAQ: ANL), una empresa global de biotecnología en etapa clínica, ha nombrado a Roger Sawhney, M.D. en su Junta Directiva, a partir del 8 de agosto de 2024. El Dr. Sawhney aporta casi 30 años de experiencia financiera y estratégica en la industria biofarmacéutica. Actualmente se desempeña como Director Financiero de LB Pharmaceuticals y ha ocupado puestos de liderazgo en varias empresas farmacéuticas y de inversión, incluyendo Garuda Therapeutics, Omega Therapeutics, KKR & Co. Inc. y Novartis AG.
El CEO Carsten Lu dio la bienvenida al Dr. Sawhney, destacando su valiosa experiencia financiera tanto desde la perspectiva corporativa farmacéutica como de inversiones en salud. El Dr. Sawhney expresó su entusiasmo por unirse a la misión de Adlai Nortye de desarrollar terapias innovadoras contra el cáncer y transformar el cáncer mortal en una enfermedad crónica y, eventualmente, curable.
Adlai Nortye (NASDAQ: ANL), 글로벌 임상 단계 생명공학 회사가 Roger Sawhney, M.D.를 이사회에 임명했습니다, 2024년 8월 8일부터 효력이 발생합니다. Sawhney 박사는 생명 약품 산업에서 거의 30년의 재무 및 전략 전문성을 보유하고 있습니다. 그는 현재 LB Pharmaceuticals의 최고 재무 책임자로 재직 중이며, Garuda Therapeutics, Omega Therapeutics, KKR & Co. Inc., 그리고 Novartis AG를 포함한 여러 제약 및 투자 회사에서 리더십 직책을 역임했습니다.
CEO Carsten Lu는 제약 기업과 의료 투자 관점에서 그의 귀중한 재무 경험을 강조하며 Sawhney 박사를 환영했습니다. Sawhney 박사는 Adlai Nortye의 혁신적인 암 치료제를 개발하고 치명적인 암을 만성이자 결국에는 치유 가능한 질병으로 변화시키겠다는 사명에 합류하게 되어 기쁘다고 전했습니다.
Adlai Nortye (NASDAQ: ANL), une entreprise biopharmaceutique mondiale en phase clinique, a nommé Roger Sawhney, M.D. au sein de son Conseil d'Administration, avec effet au 8 août 2024. Le Dr Sawhney apporte près de 30 ans d'expertise financière et stratégique dans l'industrie biopharmaceutique. Il exerce actuellement la fonction de Directeur Financier de LB Pharmaceuticals et a occupé des postes de direction au sein de diverses sociétés pharmaceutiques et d'investissement, notamment Garuda Therapeutics, Omega Therapeutics, KKR & Co. Inc. et Novartis AG.
Le PDG Carsten Lu a accueilli le Dr Sawhney, soulignant son expérience financière précieuse tant du point de vue des entreprises pharmaceutiques que des investissements en santé. Le Dr Sawhney a exprimé son enthousiasme à l'idée de rejoindre la mission d'Adlai Nortye de développer des thérapies innovantes contre le cancer et de transformer le cancer mortel en une maladie chronique et finalement curable.
Adlai Nortye (NASDAQ: ANL), ein global tätiges Biotechnologieunternehmen in klinischer Phase, hat Roger Sawhney, M.D. in seinen Vorstand berufen, mit Wirkung zum 8. August 2024. Dr. Sawhney bringt fast 30 Jahre Erfahrung in finanziellen und strategischen Belangen in der Biopharma-Industrie mit. Derzeit ist er CFO von LB Pharmaceuticals und hat Führungspositionen in verschiedenen Pharma- und Investmentunternehmen innegehabt, darunter Garuda Therapeutics, Omega Therapeutics, KKR & Co. Inc. und Novartis AG.
CEO Carsten Lu begrüßte Dr. Sawhney und hob seine wertvolle finanzielle Erfahrung aus der Perspektive der Pharmaunternehmen sowie der Gesundheitsinvestitionen hervor. Dr. Sawhney zeigte sich begeistert, der Mission von Adlai Nortye beizutreten, innovative Krebstherapien zu entwickeln und tödlichen Krebs in eine chronische und schließlich heilbare Erkrankung zu transformieren.
- Appointment of Roger Sawhney, M.D. to the Board of Directors, bringing 30 years of financial and strategic expertise in biopharma
- Dr. Sawhney's extensive experience in pharmaceutical corporate and healthcare investment sectors
- Potential for fresh insights and strengthened leadership in advancing the company's cancer therapy development mission
- None.
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a global clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Mr. Roger Sawhney, M.D. to its Board of Directors as a director, effective August 8, 2024. Dr. Sawhney has nearly 30 years of financial and strategic expertise spanning the biopharma industry.
“Dr. Sawhney brings a wealth of financial experience from both the pharmaceutical corporate sector and healthcare investment perspectives,” said Carsten Lu, CEO and Chairman of Adlai Nortye. “Our team welcomes Dr. Sawhney to our Board of Directors, and we look forward to incorporating his insights as we advance our important mission.”
“I am honored to join Adlai Nortye's Board and excited to work with such a talented and dedicated team to bring more innovative cancer therapies to patients worldwide,” said Dr. Sawhney. “I am deeply impressed by Adlai Nortye’s extensive research and development capabilities and the team’s mission to transform deadly cancer into a chronic and eventually curable disease.”
Dr. Sawhney currently serves as the Chief Financial Officer of LB Pharmaceuticals, a neuro-psych focused Company, based in New York City.
From September 2022 to December 2023, Dr. Sawhney served as the Chief Financial Officer of Garuda Therapeutics, Inc. From March 2020 to May 2022, Dr. Sawhney served as the Chief Financial Officer of Omega Therapeutics, Inc., a pioneer in mRNA-based therapeutics for precision gene modulation, and he served as the Chief Business Officer of Omega from May 2022 to September 2022.
From September 2018 to August 2020, Dr. Sawhney served at KKR & Co. Inc., a global investment firm, as Director of its healthcare investment platform in the Americas where his work focused on investments across private and growth equity in the healthcare sector. From July 2009 to August 2012, Dr. Sawhney served as Senior Vice President and Head of Global Corporate Strategy for Novartis AG, as well as Senior Vice President of Corporate Strategy and Business Development for Outcome Health from February 2017 to February 2018. Dr. Sawhney has also served as Partner with Bain & Company from August 2012 to February 2017 and the Boston Consulting Group from 1996 to 2009, where he managed numerous client engagements across the life sciences, med-tech and digital health sectors.
Dr. Sawhney holds an M.D. from Harvard Medical School and a B.A. in Economics from Stanford University.
About Adlai Nortye
Adlai Nortye (NASDAQ: ANL) is a global clinical-stage company focused on the development of innovative targeted and immune-modulating cancer therapies, with global R&D centers in the U.S. and China. The Company is advancing a robust oncology pipeline, with our lead candidate Buparlisib (AN2025), a pan-PI3K inhibitor, currently being evaluated in a registrational Phase 3 trial (NCT04338399) in patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-PD(L)1 treatment. Additionally, we are advancing multiple drug candidates including AN4005, an oral small molecule PD-L1 inhibitor, AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (“APC”) modulator, and AN9025, an oral small molecule pan-RAS inhibitor.
Forward-Looking and Cautionary Statements
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets” and similar statements. Among other things, statements that are not historical facts, including statements about the Company’s beliefs and expectations, the business outlook and quotations from management in this announcement, as well as the Company’s strategic and operational plans, are or contain forward-looking statements.
The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. Factors that could cause the Company's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of the Company's preclinical studies, clinical trials and other therapeutic candidate development efforts; the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results will be predictive of real-world results; the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of the Company's therapeutic candidates; the Company's ability to establish, manage, and maintain corporate collaborations, as well as the ability of its collaborators to execute on their development and commercialization plans; the implementation of the Company‘s business model and strategic plans for its business and therapeutic candidates; the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of the Company's expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the PRC and United States or elsewhere. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Contacts:
Investor Relations:
Charles Zhou
Amanda Kong
Adlai Nortye Ltd.
ir@adlainortye.com
FAQ
Who is the new Board member appointed by Adlai Nortye (ANL) on August 8, 2024?
What is Roger Sawhney's current role outside of Adlai Nortye (ANL)?
What experience does Roger Sawhney bring to Adlai Nortye's (ANL) Board?
What is Adlai Nortye's (ANL) primary focus as a biotechnology company?
